Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Adma Biologics Inc shares valued at $183,960 were purchased by Guiheen Lawrence P. on May 21 ’25. At $20.44 per share, Guiheen Lawrence P. acquired 9,000 shares.
Also, Grossman Adam S sold 21,000 shares, netting a total of over 408,450 in proceeds. Following the sale of shares at $19.45 each, the insider now holds 2,049,850 shares.
Before that, Grossman Adam S had sold 21,000 shares from its account. In a trade valued at $450,660, the President and CEO traded Adma Biologics Inc shares for $21.46 each. Upon closing the transaction, the insider’s holdings decreased to 21,000 shares, worth approximately $41.45 million.
Analysts at Mizuho started covering the stock with ‘”a Buy”‘ outlook in a report released in mid October. As of November 11, 2021, Raymond James has increased its “an Outperform” rating to a “Strong buy” for ADMA. Earlier on November 09, 2021, Cantor Fitzgerald initiated its rating. Their recommendation was “an Overweight” for ADMA stock.
Analyzing ADMA Stock Performance
During the last five days, there has been a surge of approximately 5.00%. Over the course of the year, Adma Biologics Inc shares have jumped approximately 17.55%. Shares of the company reached a 52-week high of $25.67 on 04/28/25 and a 52-week low of $13.50 on 03/04/25.
Support And Resistance Levels for Adma Biologics Inc (ADMA)
According to the 24-hour chart, there is a support level at 19.95, which, if violated, would cause prices to drop to 19.74. In the upper region, resistance lies at 20.35. The next price resistance is at 20.54. RSI (Relative Strength Index) is 46.14 on the 14-day chart, showing neutral technical sentiment.
